Alnylam Pharmaceuticals
ALNY
#445
Rank
NZ$90.61 B
Marketcap
NZ$685.86
Share price
0.50%
Change (1 day)
59.25%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): NZ$0.21 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$3.21 Billion. In 2024 the company made an earning of -NZ$0.41 Billion, an increase over its 2023 earnings that were of -NZ$0.54 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$0.21 B-153.81%
2024 -NZ$0.41 Billion-24.59%
2023 -NZ$0.54 Billion-67.84%
2022 -NZ$1.67 Billion36.93%
2021 -NZ$1.22 Billion-8.04%
2020 -NZ$1.32 Billion-15.66%
2019 -NZ$1.57 Billion12.23%
2018 -NZ$1.4 Billion62.91%
2017 -NZ$0.86 Billion17.78%
2016 -NZ$0.73 Billion43.44%
2015 -NZ$0.51 Billion60.69%
2014 -NZ$0.32 Billion98.2%
2013 -NZ$0.16 Billion
2011 -NZ$93.84 Million27.48%
2010 -NZ$73.61 Million-10.92%
2009 -NZ$82.63 Million95.77%
2008 -NZ$42.21 Million
2006 -NZ$67.62 Million-9.13%
2005 -NZ$74.42 Million34.74%
2004 -NZ$55.23 Million36.79%
2003 -NZ$40.38 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Arrowhead Pharmaceuticals
ARWR
NZ$0.24 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
NZ$8.80 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$0.44 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.28 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$81.19 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$28.10 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$15.57 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
NZ$3.03 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel